Digoxin-specific antibody fragments in the treatment of digoxin toxicity

References

• Goldberger ZD, Goldberger AL. Therapeutic ranges of serum digoxin concentrations in patients with heart failure. Am J Cardiol 2012; 109:1818–1821.
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365:2002–2012.
   PubMed Web of Science ®Google Scholar
• Haynes K, Hennessy S, Localio AR, Cohen A, Leonard CE, Kimmel SE, et al. Increased risk of digoxin toxicity following hospitalization. Pharmacoepidemiol Drug Saf 2009; 18:28–35.
   PubMed Web of Science ®Google Scholar
• Butler VP Jr, Chen JP. Digoxin-specific antibodies. Proc Natl Acad Sci U S A 1967; 57:71–78.
   PubMed Web of Science ®Google Scholar
• Smith TW, Haber E, Yeatman L, Butler VP, Jr. Reversal of advanced digoxin intoxication with Fab fragments of digoxin-specific antibodies. N Engl J Med 1976; 294:797–800.
   PubMed Web of Science ®Google Scholar
• Taboulet P, Baud FJ, Bismuth C. Clinical features and management of digitalis poisoning–rationale for immunotherapy. J Toxicol Clin Toxicol 1993; 31:247–260.
   PubMed Web of Science ®Google Scholar
• Hickey AR, Wenger TL, Carpenter VP, Tilson HH, Hlatky MA, Furberg CD, et al. Digoxin Immune Fab therapy in the management of digitalis intoxication: safety and efficacy results of an observational surveillance study. J Am Coll Cardiol 1991; 17:590–598.
   PubMed Web of Science ®Google Scholar
• Lapostolle F, Borron SW, Verdier C, Arnaud F, Couvreur J, Megarbane B, et al. Assessment of digoxin antibody use in patients with elevated serum digoxin following chronic or acute exposure. Intensive Care Med 2008; 34:1448–1453.
   PubMed Web of Science ®Google Scholar
• Bilbault P, Oubaassine R, Rahmani H, Lavaux T, Castelain V, Sauder P, Schneider F. Emergency step-by-step specific immunotherapy in severe digoxin poisoning: an observational cohort study. Eur J Emerg Med 2009; 16:145–149.
   PubMed Web of Science ®Google Scholar
• Camphausen C, Haas NA, Mattke AC. Successful treatment of oleander intoxication (cardiac glycosides) with digoxin-specific Fab antibody fragments in a 7-year-old child: case report and review of literature. Z Kardiol 2005; 94:817–823.
   PubMedGoogle Scholar
• Eddleston M, Rajapakse S, Rajakanthan, Jayalath S, Sjostrom L, Santharaj W, et al. Anti-digoxin Fab fragments in cardiotoxicity induced by ingestion of yellow oleander: a randomised controlled trial. Lancet 2000; 355:967–972.
   PubMed Web of Science ®Google Scholar
• Safadi R, Levy I, Amitai Y, Caraco Y. Beneficial effect of digoxin-specific Fab antibody fragments in oleander intoxication. Arch Intern Med 1995; 155:2121–2125.
   PubMed Web of Science ®Google Scholar
• Shumaik GM, Wu AW, Ping AC. Oleander poisoning: treatment with digoxin-specific Fab antibody fragments. Ann Emerg Med 1988; 17:732–735.
   PubMed Web of Science ®Google Scholar
• Brubacher JR, Ravikumar PR, Bania T, Heller MB, Hoffman RS. Treatment of toad venom poisoning with digoxin-specific Fab fragments. Chest 1996; 110:1282–1288.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Lopez AE, Wells A, Olsen M, Actor J. The Fab fragment of anti-digoxin antibody (digibind) binds digitoxin-like immunoreactive components of Chinese medicine Chan Su: monitoring the effect by measuring free digitoxin. Clin Chim Acta 2001; 309:91–5.
   PubMed Web of Science ®Google Scholar
• Dasgupta A, Szelei-Stevens KA. Neutralization of free digoxin-like immunoreactive components of oriental medicines Dan Shen and Lu-Shen-Wan by the Fab fragment of antidigoxin antibody (Digibind). Am J Clin Pathol 2004; 121:276–281.
   PubMed Web of Science ®Google Scholar
• Oubaassine R, Weckering M, Kessler L, Breidert M, Roegel JC, Eftekhari P. Insulin interacts directly with Na(+)/K(+)ATPase and protects from digoxin toxicity. Toxicology 2012; 299:1–9.
   PubMed Web of Science ®Google Scholar
• Gawarammana I, Mohamed F, Bowe SJ, Rathnathilake A, Narangoda SK, Azher S, et al. Fructose-1, 6-diphosphate (FDP) as a novel antidote for yellow oleander-induced cardiac toxicity: a randomized controlled double blind study. BMC Emerg Med 2010; 10:15.
   PubMedGoogle Scholar
• Mahdyoon H, Battilana G, Rosman H, Goldstein S, Gheorghiade M. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. Am Heart J 1990; 120:1189–1194.
   PubMed Web of Science ®Google Scholar
• Kirrane BM, Olmedo RE, Nelson LS, Mercurio-Zappala M, Howland MA, Hoffman RS. Inconsistent approach to the treatment of chronic digoxin toxicity in the United States. Hum Exp Toxicol 2009; 28:285–292.
   PubMed Web of Science ®Google Scholar
• Eyer F, Steimer W, Muller C, Zilker T. Free and total digoxin in serum during treatment of acute digoxin poisoning with Fab fragments: case study. Am J Crit Care 2010; 19:391–387.
   PubMed Web of Science ®Google Scholar
• Smolarz A, Roesch E, Lenz E, Neubert H, Abshagen P. Digoxin specific antibody (Fab) fragments in 34 cases of severe digitalis intoxication. J Toxicol Clin Toxicol 1985; 23:327–340.
   PubMed Web of Science ®Google Scholar
• Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990; 81:1744–1752.
   PubMed Web of Science ®Google Scholar
• Cohen AF, Kroon R, Schoemaker HC, Breimer DD, Van Vliet-Verbeek A, Brandenburg HC. The bioavailability of digoxin from three oral formulations measured by a specific h.p.l.c. assay. Br J Clin Pharmacol 1993; 35:136–142.
   PubMed Web of Science ®Google Scholar
• Ochs HR, Greenblatt DJ, Bodem G, Harmatz JS. Dose-independent pharmacokinetics of digoxin in humans. Am Heart J 1978; 96:507–511.
   PubMed Web of Science ®Google Scholar
• Renard C, Grene-Lerouge N, Beau N, Baud F, Scherrmann JM. Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br J Clin Pharmacol 1997; 44:135–138.
   PubMed Web of Science ®Google Scholar
• Chen R, Zou SL, Wang ML, Jiang Y, Xue H, Qian CY, Xia ZL. Population pharmacokinetics of digoxin in elderly patients. Eur J Drug Metab Pharmacokinet 2013; 38:115–121.
   PubMed Web of Science ®Google Scholar
• Koup JR, Jusko WJ, Elwood CM, Kohli RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther 1975; 18:9–21.
   PubMed Web of Science ®Google Scholar
• Reuning RH, Sams RA, Notari RE. Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol New Drugs 1973; 13:127–141.
   PubMedGoogle Scholar
• Bauman JL, Didomenico RJ, Galanter WL. Mechanisms, manifestations, and management of digoxin toxicity in the modern era. Am J Cardiovasc Drugs 2006; 6:77–86.
   PubMedGoogle Scholar
• Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003; 289:871–878.
   PubMed Web of Science ®Google Scholar
• Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013; 61:2495–2502.
   PubMed Web of Science ®Google Scholar
• Sinclair AJ, Hewick DS, Johnston PC, Stevenson IH, Lemon M. Kinetics of digoxin and anti-digoxin antibody fragments during treatment of digoxin toxicity. Br J Clin Pharmacol 1989; 28:352–356.
   PubMed Web of Science ®Google Scholar
• van der Aa GC. [Pharmacokinetics of digoxin in the aged]. Tijdschr Gerontol Geriatr 1984; 15:67–71.
   PubMedGoogle Scholar
• Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Sailstad JM, Vlasses PH, et al. Disposition of digoxin immune Fab in patients with kidney failure. Clin Pharmacol Ther 1993; 54:388–394.
   PubMed Web of Science ®Google Scholar
• Allen NM, Dunham GD, Sailstad JM, Findlay JW. Clinical and pharmacokinetic profiles of digoxin immune Fab in four patients with renal impairment. DICP 1991; 25:1315–1320.
   PubMedGoogle Scholar
• Flanagan RJ, Jones AL. Fab antibody fragments: some applications in clinical toxicology. Drug Saf 2004; 27:1115–1133.
   PubMed Web of Science ®Google Scholar
• Ujhelyi MR, Robert S. Pharmacokinetic aspects of digoxin-specific Fab therapy in the management of digitalis toxicity. Clin Pharmacokinet 1995; 28:483–493.
   PubMed Web of Science ®Google Scholar
• Ujhelyi MR, Colucci RD, Cummings DM, Green PJ, Robert S, Vlasses PH, Zarowitz BJ. Monitoring serum digoxin concentrations during digoxin immune Fab therapy. DICP 1991; 25:1047–1049.
   PubMedGoogle Scholar
• Schaumann W, Kaufmann B, Neubert P, Smolarz A. Kinetics of the Fab fragments of digoxin antibodies and of bound digoxin in patients with severe digoxin intoxication. Eur J Clin Pharmacol 1986; 30:527–533.
   PubMed Web of Science ®Google Scholar
• Cano NJ, Sabouraud AE, Debray M, Scherrmann JM. Dose-dependent reversal of digoxin-inhibited activity of an in vitro Na + K+ ATPase model by digoxin-specific antibody. Toxicol Lett 1996; 85:107–111.
   PubMed Web of Science ®Google Scholar
• Zucker AR, Lacina SJ, DasGupta DS, Fozzard HA, Mehlman D, Butler VP Jr, et al. Fab fragments of digoxin-specific antibodies used to reverse ventricular fibrillation induced by digoxin ingestion in a child. Pediatrics 1982; 70:468–471.
   PubMed Web of Science ®Google Scholar
• Husby P, Farstad M, Brock-Utne JG, Koller ME, Segadal L, Lund T, Ohm OJ. Immediate control of life-threatening digoxin intoxication in a child by use of digoxin-specific antibody fragments (Fab). Paediatr Anaesth 2003; 13:541–549.
   PubMedGoogle Scholar
• Spiegel A, Marchlinski FE. Time course for reversal of digoxin toxicity with digoxin-specific antibody fragments. Am Heart J 1985; 109:1397–1399.
   PubMed Web of Science ®Google Scholar
• Lemon M, Andrews DJ, Binks AM, Georgiou GA. Concentrations of free serum digoxin after treatment with antibody fragments. Br Med J (Clin Res Ed) 1987; 295:1520–1521.
   PubMed Web of Science ®Google Scholar
• Ujhelyi MR, Robert S, Cummings DM, Colucci RD, Green PJ, Sailstad J, et al. Influence of digoxin immune Fab therapy and renal dysfunction on the disposition of total and free digoxin. Ann Intern Med 1993; 119:273–277.
   PubMed Web of Science ®Google Scholar
• Weller P, Peters U, Dickmanns HA, Hespe TH, Adam M, Allolio B, et al.[Antidigoxin Fab-fragments in suicidal digoxin poisoning. Successful treatment of recurrent ventricular fibrillation]. Dtsch Med Wochenschr 1983; 108:1437–1440.
   PubMed Web of Science ®Google Scholar
• Rossi R, Leititis JU, Hagel KJ, Smolarz A, Brandis M. Severe digoxin intoxication in a child treated by infusion of digoxin-specific Fab-antibody-fragments. Eur J Pediatr 1984; 142:138–140.
   PubMed Web of Science ®Google Scholar
• Hursting MJ, Raisys VA, Opheim KE, Bell JL, Trobaugh GB, Smith TW. Determination of free digoxin concentrations in serum for monitoring Fab treatment of digoxin overdose. Clin Chem 1987; 33:1652–1655.
   PubMed Web of Science ®Google Scholar
• Kearns GL, Moss MM, Clayton BD, Hewett DD. Pharmacokinetics and efficacy of digoxin specific Fab fragments in a child following massive digoxin overdose. J Clin Pharmacol 1989; 29: 901–908.
   PubMed Web of Science ®Google Scholar
• Lapostolle F, Borron SW, Verdier C, Taboulet P, Guerrier G, Adnet F, et al. Digoxin-specific Fab fragments as single first-line therapy in digitalis poisoning. Crit Care Med 2008; 36:3014–3018.
   PubMed Web of Science ®Google Scholar
• Bateman DN. Digoxin-specific antibody fragments: how much and when? Toxicol Rev 2004; 23:135–143.
   PubMedGoogle Scholar
• Sanaei-Zadeh H, Valian Z, Zamani N, Farajidana H, Mostafazadeh B. Clinical features and successful management of suicidal digoxin toxicity without use of digoxin-specific antibody (Fab) fragments–is it possible? Trop Doct 2011; 41:108–110.
   PubMed Web of Science ®Google Scholar
• Abad-Santos F, Carcas AJ, Ibanez C, Frias J. Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. Ther Drug Monit 2000; 22:163–168.
   PubMed Web of Science ®Google Scholar
• Rabkin SW, Grupp G. A two compartment open model for digoxin pharmacokinetics in patients receiving a wide range of digoxin doses. Acta Cardiol 1975; 30:343–351.
   PubMed Web of Science ®Google Scholar
• Kramer WG, Lewis RP, Cobb TC, Forester WF Jr, Visconti JA, Wanke LA, et al. Pharmacokinetics of digoxin: comparison of a two- and a three-compartment model in man. J Pharmacokinet Biopharm 1974; 2:299–312.
   PubMedGoogle Scholar
• Cheng JW, Charland SL, Shaw LM, Kobrin S, Goldfarb S, Stanek EJ, Spinler SA. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. Pharmacotherapy 1997; 17:584–590.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick CH. Allergic histories and reactions of patients treated with digoxin immune Fab (ovine) antibody. The Digibind Study Advisory Panel. Am J Emerg Med 1991; 9:7–10; discussion 33–4.
   PubMed Web of Science ®Google Scholar
• Mauskopf JA, Wenger TL. Cost-effectiveness analysis of the use of digoxin immune Fab (ovine) for treatment of digoxin toxicity. Am J Cardiol 1991; 68:1709–1714.
   PubMed Web of Science ®Google Scholar
• Gandhi AJ, Vlasses PH, Morton DJ, Bauman JL. Economic impact of digoxin toxicity. Pharmacoeconomics 1997; 12:175–181.
   PubMed Web of Science ®Google Scholar
• DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL. Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity. J Cardiovasc Pharmacol Ther 2000; 5:77–85.
   PubMedGoogle Scholar
• Smith TW, Butler VP Jr, Haber E, Fozzard H, Marcus FI, Bremner WF, et al. Treatment of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments: experience in 26 cases. N Engl J Med 1982; 307:1357–1362.
   PubMed Web of Science ®Google Scholar
• Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 63 severely digitalis-toxic patients with digoxin-specific antibody fragments. J Am Coll Cardiol 1985; 5:118A–123A.
   Web of Science ®Google Scholar
• Antman EM, Arnold JM, Friedman PL, Smith TW. Pharmacokinetic drug interactions between digoxin and antiarrhythmic agents and calcium channel blocking agents: an appraisal of study methodology. Cardiovasc Drugs Ther 1987; 1:183–189.
   PubMedGoogle Scholar
• Woolf AD, Wenger TL, Smith TW, Lovejoy FH Jr. Results of multicenter studies of digoxin-specific antibody fragments in managing digitalis intoxication in the pediatric population. Am J Emerg Med 1991; 9:16–20; discussion 33–4.
   PubMed Web of Science ®Google Scholar
• Schaeffer TH, Mlynarchek SL, Stanford CF, Delgado J, Holstege CP, Olsen D, Bogdan GM. Treatment of chronically digoxin-poisoned patients with a newer digoxin immune fab–a retrospective study. J Am Osteopath Assoc 2010; 110:587–592.
   PubMedGoogle Scholar
• Abernethy DR, Greenblatt DJ, Smith TW. Digoxin disposition in obesity: clinical pharmacokinetic investigation. Am Heart J 1981; 102:740–744.
   PubMed Web of Science ®Google Scholar
• Mitchell SJ, Kirkpatrick CM, Le Couteur DG, Naganathan V, Sambrook PN, Seibel MJ, et al. Estimation of lean body weight in older community-dwelling men. Br J Clin Pharmacol 2010; 69:118–127.
   PubMed Web of Science ®Google Scholar
• Forbes GB, Reina JC. Adult lean body mass declines with age: some longitudinal observations. Metabolism 1970; 19:653–663.
   PubMed Web of Science ®Google Scholar